ClinicalTrials.gg
CompletedNCT03702413Updated Jul 12, 2022

Randomized Controlled Trial of Endovascular Therapy for Acute Large Vessel Occlusion With Large Ischemic Core

An interventional study of Endovascular treatment in Mechanical Thrombectomy and Large Ischemic Core, sponsored by Hyogo Medical University. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-12.

Sponsored by Hyogo Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.

Enrollment
21st of 35
203 · median 270
Started
2018
with 3 others
No phase
10 of 43
1 open now
Registered
24th of 43
by date
Lead sponsor
5 of 43
Hyogo Medical University

Among the 43 studies in Ischemic Stroke with a site in Japan, this one is the 21st largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2018, is one of 10 with no phase, and was the 24th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ischemic Stroke with a site in Japan, or all of them as a file.
02

Study summary

RESCUE-Japan LIMIT(Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism Japan Large IscheMIc core Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to compare the effectiveness of endovascular treatment as compared to best medical treatment alone in the acute ischemic stroke patients with an low ASPECTS (CT-ASPECTS 3-5 or DWI-ASPECTS 3-5).

The purpose of this study is to investigate the efficacy of endovascular treatment for acute large vessel occlusion with large ischemic core (CT-ASPECT score 3-5 or DWI-ASPECT score 3-5).

Read the detailed description

In the American Heart Association guideline 2018, endovascular therapy (EVT) has been strongly recommended as class of recommendation (COR) I for for the patients with acute cerebral large vessel occlusion (LVO), the Alberta Stroke Program Early CT Score (ASPECTS) 6 or more. The efficacy of EVT for the patients with low ASPECTS remains unclear.

This study is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to compare the effectiveness of endovascular treatment as compared to best medical treatment alone for acute large vessel occlusion patients with large ischemic core (ASPECTS 3-5 or DWI-ASPECTS 3-5).

Up to 200 subjects will be enrolled in the study and randomized for the Intention to treat analysis set. The randomization will be stratified by treatment institutes, patient's age (less than 75 years old or not), time from symptom onset (0-2 hours or more than 2 hours), and stroke severity (NIHSS 21 or more/less than 21), and administration of rt-PA.

Subjects who meet the inclusion criteria will be randomized in a 1:1 ratio to one of the following two treatment arms: Arm 1: best medical treatment Arm 2: best medical treatment plus endovascular treatment

Primary outcome of this study is to investigate efficacy of endivascular treatment in acute stroke patients with large ischemic core (ASPECTS 3-5 or DWI-ASPECTs 3-5) as compared to best medical treatment alone.

Approximately 40 sites in Japan Patients presenting with acute ischemic stroke (AIS) based on focal occlusion in the M1 segment of the middle cerebral artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA), determined by Magnetic Resonance Angiography (MRA) or Computed Tomographic Angiography (CTA), and who meet all eligibility criteria will be considered for study enrollment.

03

Conditions studied

  • Mechanical Thrombectomy
  • Large Ischemic Core

Browse trials for

Keywords

  • Acute cerebral infarction due to large vessel occlusion
  • Mechanical thrombectomy
  • Ischemic stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Acute cerebral infarction
  2. Age ≥ 18
  3. NIHSS ≥ 6
  4. Prestroke Modified Rankin Score 0-1
  5. ICA or M1 Occlusion on CT angiography or MR angiography
  6. ASPECTS 3-5 or DWI-ASPECTS 3-5
  7. Randamization can be finished within 6 hours from last known well time, or 6 to 24 hours from last well known well time without positive lesion on MRI-FLAIR image.
  8. Endovascular treatment can be initiatedwithin 60 minutes from randomization
  9. Patient or Legally Authorized Representative has signed the form

Exclusion criteria

Exclusion Criteria:

  1. Significant mass effect with midline shift
  2. Known allergy to contrast agents
  3. Evidence of acute intracranial hemorrhage
  4. Female who is pregnant or suspicision of pregnant
  5. Clinical evidence of chronic occlusion
  6. High risk of hemorrhage ( \< 40,000 /µL, > 50 second or PT-INR > 3.0)
  7. Participating in any other therapeutic trial
  8. Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • No intervention
    Best medical treatment

    Best medical treatment

  • Experimental
    Endovascular treatment

    Best medical treatment plus endovascular treatment

    Procedure: Endovascular treatment

Interventions

  • ProcedureEndovascular treatment

    Acute thrombectomy

06

What researchers measure

Primary outcomes

  1. modified Rankin Scale ≤3 at 90 days

    The primary endpoint of the trial is the modified Rankin Scale (mRS) ≤3 at 90 days post-stroke.The scale runs from 0-6 with 0 being perfect health without symptoms to 6 being death. 0: No symptoms. 1. No significant disability. Able to carry out all usual activities, despite some symptoms. 2. Slight disability. Able to look after own a符airs without assistance, but unable to carry out all previous activities. 3. Moderate disability. Requires some help, but able to walk unassisted. 4. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. Severe disability. Requires constant nursing care and a悦ention, bedridden, incontinent. 6. Dead.

    Time frame: 90 days

Secondary outcomes

  1. modified Rankin Scale≤2 at 90 days

    Functional independence as difined by modified Rankin ScalemRS≤2 at 90 days

    Time frame: 90 days

  2. modified Rankin Scale≤1 at 90 days

    Excellent outcome as difined by modified Rankin Scale≤1 at 90 days

    Time frame: 90 days

  3. Distribution of patients across the ordinal modified Rankin scale

    The difference in linear trends in ordinal mRS outcomes between treatment groups (mRS shift analysis)

    Time frame: 90 days

  4. NIHSS improvement 8 points or more at 48 hours

    Early improvement of neulogical findings

    Time frame: 48 hours

  5. Symptomatic intracranial hemorrhage within 48 hours

    Defined as NIHSS worsening of 4 or more points associated with ICH within 48 hours of randomization

    Time frame: 48 hours

  6. Intracranial hemorrhage within 48 hours

    The incidence of hemorrhage

    Time frame: 48 hours

  7. Death

    Death due to any cause at 90 days

    Time frame: 90 days

  8. Recurrence of cerebral infarction within 90 days

    Recurrence of cerebral infarction

    Time frame: 90 days

  9. Propotion of subjects who required decompressive craniectomy within 7 days

    Propotion of subjects who had space-occupying infarction (malignant brain edema) and requred decompressive craniectomy within 7 days

    Time frame: 7 days

07

Study locations

1 site
  • Hyogo collage of Medicine
    Nishinomiya, Hyogo 665-8501, Japan
08

References and documents

Publications

  • Uchida K, Shindo S, Yoshimura S, Toyoda K, Sakai N, Yamagami H, Matsumaru Y, Matsumoto Y, Kimura K, Ishikura R, Yoshida A, Inoue M, Beppu M, Sakakibara F, Shirakawa M, Morimoto T; RESCUE-Japan LIMIT Investigators. Association Between Alberta Stroke Program Early Computed Tomography Score and Efficacy and Safety Outcomes With Endovascular Therapy in Patients With Stroke From Large-Vessel Occlusion: A Secondary Analysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-Japan Large Ischemic Core Trial (RESCUE-Japan LIMIT). JAMA Neurol. 2022 Dec 1;79(12):1260-1266. doi: 10.1001/jamaneurol.2022.3285. Erratum In: JAMA Neurol. 2023 Feb 1;80(2):216. doi: 10.1001/jamaneurol.2022.4331. PubMed 36215044 ↗
  • Yoshimura S, Sakai N, Yamagami H, Uchida K, Beppu M, Toyoda K, Matsumaru Y, Matsumoto Y, Kimura K, Takeuchi M, Yazawa Y, Kimura N, Shigeta K, Imamura H, Suzuki I, Enomoto Y, Tokunaga S, Morita K, Sakakibara F, Kinjo N, Saito T, Ishikura R, Inoue M, Morimoto T. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N Engl J Med. 2022 Apr 7;386(14):1303-1313. doi: 10.1056/NEJMoa2118191. Epub 2022 Feb 9. PubMed 35138767 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Dec 2021, 36 months.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 36 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2018
First posted
Oct 11, 2018
StartActual
Nov 30, 2018
Primary completionActual
Dec 21, 2021
CompletionActual
Mar 30, 2022
Last update
Jul 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03702413
Lead sponsor
Hyogo Medical University
Responsible party
Shinichi Yoshimura (Department of Neurosurgery, Hyogo Medical University) — Principal investigator
First posted
Oct 11, 2018
Start date
Nov 30, 2018
Primary completion
Dec 21, 2021
Completion
Mar 30, 2022
Last update
Jul 12, 2022

Study contacts

Shinichi Yoshimura, phD
study chair · Hyogo Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion